ARA-290 / cibinetide
An erythropoietin-derived investigational peptide.
Investigational / no FDA-approved-treatment claim
An erythropoietin-derived investigational peptide.
Reviewed October 10, 2026. Product and route distinctions stay attached to the source; this is not a treatment recommendation.
Purported uses, not established benefits
Proposed uses include reducing symptoms related to small-fiber neuropathy and supporting tissue protection.
The cited randomized pilot involved sarcoidosis patients with small-fiber neuropathy. A small disease-specific trial does not establish general pain relief, nerve regeneration or FDA approval.
Evidence and source limits
The source linked here describes research or investigational use. It does not establish an FDA-approved indication for this compound or for a research-chemical product. A claimed use is not an established benefit.
Product identity, purity, route, safety and suitability remain separate questions. Research-purpose-only labeling does not authorize human use. This note provides no dosing, preparation or purchase guidance.
Original source: ARA-290 / cibinetide ↗
Interpretation is limited to the source linked above. Educational source review, not independent medical review. No dosing, preparation instructions, seller links or treatment endorsement.